RNO Stock Overview
Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Rhinomed Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.04 |
| 52 Week High | AU$0.10 |
| 52 Week Low | AU$0.019 |
| Beta | 0.88 |
| 1 Month Change | 60.00% |
| 3 Month Change | 33.33% |
| 1 Year Change | -55.56% |
| 3 Year Change | -66.67% |
| 5 Year Change | -74.19% |
| Change since IPO | -99.41% |
Recent News & Updates
Recent updates
Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year
Nov 10
Is Rhinomed (ASX:RNO) Using Too Much Debt?
Mar 03Rhinomed (ASX:RNO) Is In A Strong Position To Grow Its Business
Mar 01Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation
Jul 09Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation
Mar 01Key Things To Understand About Rhinomed's (ASX:RNO) CEO Pay Cheque
Jan 25How Many Rhinomed Limited (ASX:RNO) Shares Did Insiders Buy, In The Last Year?
Dec 20Shareholder Returns
| RNO | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -7.0% | 3.3% | 0.5% |
| 1Y | -55.6% | -10.0% | 7.4% |
Return vs Industry: RNO underperformed the Australian Pharmaceuticals industry which returned 61.8% over the past year.
Return vs Market: RNO underperformed the Australian Market which returned 9.6% over the past year.
Price Volatility
| RNO volatility | |
|---|---|
| RNO Average Weekly Movement | 26.2% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.9% |
| 10% least volatile stocks in AU Market | 3.0% |
Stable Share Price: RNO's share price has been volatile over the past 3 months.
Volatility Over Time: RNO's weekly volatility has increased from 19% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | Michael Johnson | www.rhinomed.global |
Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. The company offers wearable nasal technology that improve breathing, sleeping, and maintaining health and diagnose disease. Its products include Turbine for enhanced breathing in sports; Mute, which helps to breath more and snore less; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab.
Rhinomed Limited Fundamentals Summary
| RNO fundamental statistics | |
|---|---|
| Market cap | AU$11.51m |
| Earnings (TTM) | -AU$10.91m |
| Revenue (TTM) | AU$8.05m |
1.4x
P/S Ratio-1.1x
P/E RatioIs RNO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RNO income statement (TTM) | |
|---|---|
| Revenue | AU$8.05m |
| Cost of Revenue | AU$2.78m |
| Gross Profit | AU$5.28m |
| Other Expenses | AU$16.18m |
| Earnings | -AU$10.91m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.038 |
| Gross Margin | 65.53% |
| Net Profit Margin | -135.49% |
| Debt/Equity Ratio | -90.4% |
How did RNO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/20 06:10 |
| End of Day Share Price | 2024/02/19 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2023/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rhinomed Limited is covered by 2 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Josh Kannourakis | EL&C Baillieu |
| Scott Power | Morgans Financial Limited |